Nautilus Biotechnology (NAUT) to Release Quarterly Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce its earnings results before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same period in the previous year, the business posted ($0.11) EPS. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nautilus Biotechnology Price Performance

NASDAQ:NAUT opened at $2.49 on Monday. Nautilus Biotechnology has a 1-year low of $2.16 and a 1-year high of $4.65. The firm has a market capitalization of $311.50 million, a price-to-earnings ratio of -4.79 and a beta of 1.20. The company’s 50-day moving average is $2.66 and its two-hundred day moving average is $2.81.

Insiders Place Their Bets

In related news, CEO Sujal M. Patel purchased 12,044 shares of the company’s stock in a transaction on Monday, March 11th. The stock was acquired at an average cost of $2.84 per share, for a total transaction of $34,204.96. Following the completion of the transaction, the chief executive officer now directly owns 10,064,488 shares in the company, valued at $28,583,145.92. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Nautilus Biotechnology news, CEO Sujal M. Patel bought 18,854 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were purchased at an average cost of $2.89 per share, with a total value of $54,488.06. Following the purchase, the chief executive officer now directly owns 10,050,014 shares in the company, valued at $29,044,540.46. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sujal M. Patel bought 12,044 shares of Nautilus Biotechnology stock in a transaction on Monday, March 11th. The shares were acquired at an average price of $2.84 per share, for a total transaction of $34,204.96. Following the completion of the acquisition, the chief executive officer now owns 10,064,488 shares in the company, valued at $28,583,145.92. The disclosure for this purchase can be found here. Insiders acquired a total of 38,303 shares of company stock valued at $108,316 over the last quarter. 42.50% of the stock is owned by insiders.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.